Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nal-Glu
- Development stage
- Discontinued
- Lead developer
- Salk Institute for Biological Studies
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
Nal-Glu is a synthetic peptide and potent gonadotropin-releasing hormone (GnRH) receptor antagonist. It was developed to acutely inhibit the action of endogenous GnRH by competitively blocking its receptor (GnRHR), thereby suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in inhibition of ovulation in women and suppression of spermatogenesis in men. Nal-Glu has been studied for use as a contraceptive agent and for investigating reproductive endocrinology. Its development was discontinued due to challenges with synthesis cost, delivery, and side effects compared to newer antagonists[1][2][4][5].
- Other names
- Factryl
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on Nal-Glu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nal-Glu.